An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study

Blood. 2022 Aug 4;140(5):516-520. doi: 10.1182/blood.2021014604.

Authors

Si-Qi Li¹, Lan-Ping Xu¹, Yu Wang¹, Xiao-Hui Zhang¹, Huan Chen¹, Yu-Hong Chen¹, Feng-Rong Wang¹, Wei Han¹, Yu-Qian Sun¹, Chen-Hua Yan¹, Meng Lv¹, Fei-Fei Tang¹, Xiao-Dong Mo¹, Yan-Rong Liu¹, Kai-Yan Liu¹, Ying-Jun Chang¹, Xiao-Jun Huang^{1

2

3}

Affiliations

¹ Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, National Clinical Research Center for Hematologic Disease, Peking University People's Hospital & Peking University Institute of Hematology, Beijing, China.
² Peking-Tsinghua Center for Life Sciences, Beijing, China; and.
³ Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences, Beijing, China.

PMID: 35613411
DOI: 10.1182/blood.2021014604

No abstract available

MeSH terms

Flow Cytometry / methods
Humans
Leukemia, Myeloid, Acute* / diagnosis
Leukemia, Myeloid, Acute* / genetics
Neoplasm Recurrence, Local*
Neoplasm, Residual / diagnosis
Prognosis
Prospective Studies
Recurrence
Transplantation, Homologous